Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGLBiotechnology
-$1.33 today
- Market cap
- $9.25B
- Beta
- -1.06
- P/E (TTM)
- -46.9
- EPS (TTM)
- -$10.66
Volume 0.64M
Average 0.31M
MDGL Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q2 FY2026 selling, general & admin of $289.38M rose 47.0% year over year, behind the +64.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 7.8% from the prior quarter. Over 3 fiscal years it compounded at +156.7% a year.
Context
- Selling, general & admin amounted to 84.9% of revenue in FY2025, down 156.6 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 12 analysts of $1.98B (+143.8%) for the fiscal year ending Dec 2026, a step up from the +87.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $289.38M+7.8% QoQ
- Last fiscal yearDec 2025
- $813.83M+87.1% YoY
- LTMJun 2026
- $1.01B+64.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 813.83M USD
- Year-over-year change
- +87.1%
- 4-year CAGR
- +116.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 813.83M | +87.1% |
| FY2024 | 2024-12-31 | 435.06M | +302.3% |
| FY2023 | 2023-12-31 | 108.15M | +124.7% |
| FY2022 | 2022-12-31 | 48.13M | +29.0% |
| FY2021 | 2021-12-31 | 37.32M | — |
Selling, General & Admin vs competitors
How MDGL compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +64.1% is the 2nd highest of 7, against a peer median of +22.7%.
- Selling, general & admin amounts to 78.4% of revenue for MDGL, versus a peer median of 1318.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.01B USD | +64.1% | +156.7% | 78.4% | |
| LTM Jun 2026 | $102.22M USD | +6.5% | +76.0% | 1435.5% | |
| FY2025 | €53.89M EUR | +215.2% | +51.5% | 1202.1% | |
| LTM Jun 2026 | $50.71M USD | -11.8% | +44.2% | — | |
| LTM Mar 2026 | $39.04M USD | +38.9% | +14.7% | 195.2% | |
| LTM Mar 2026 | $30.16M USD | +39.3% | +17.9% | 83769.4% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $18.03M USD | +5.9% | +42.7% | — |
| Peer median (excluding MDGL) | — | +22.7% | +43.5% | 1318.8% | |
Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 180.13M | 958.4M |
| Cost of Revenue | 0 | 0 | 0 | 6.23M | 56.15M |
| Gross Profit | 0 | 0 | 0 | 173.9M | 902.26M |
| Gross Margin | — | — | — | 96.5% | 94.1% |
| Research & Development | 205.16M | 245.44M | 272.35M | 236.72M | 388.53M |
| Selling, General & Admin | 37.32M | 48.13M | 108.15M | 435.06M | 813.83M |
| Operating Expenses | 242.48M | 293.57M | 380.5M | 671.78M | 1.2B |
| Depreciation & Amortization | 405K | 467K | 527K | 1.1M | 1.51M |
| EBITDA | (241.44M) | (290.92M) | (360.39M) | (450.13M) | (264.47M) |
| EBITDA Margin | — | — | — | -249.9% | -27.6% |
| Operating Income | (242.48M) | (293.57M) | (380.5M) | (497.88M) | (300.1M) |
| Operating Margin | — | — | — | -276.4% | -31.3% |
| Interest Income | 363K | 2.19M | 19.58M | 46.65M | 37.36M |
| Interest Expense | 0 | 3.96M | 12.71M | 14.67M | 22.31M |
| Other Income / Expenses | 636K | (1.78M) | 6.87M | 31.98M | 11.81M |
| Income Before Tax | (241.85M) | (295.35M) | (373.63M) | (465.89M) | (288.28M) |
| Pre-Tax Margin | — | — | — | -258.6% | -30.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (241.85M) | (295.35M) | (373.63M) | (465.89M) | (288.28M) |
| Net Margin | — | — | — | -258.6% | -30.1% |
| EPS (Basic) | (14.63) | (17.23) | (19.99) | (21.90) | (12.85) |
| EPS (Diluted) | (14.63) | (17.23) | (19.99) | (21.90) | (12.85) |
| Weighted Avg Shares | 16.54M | 17.14M | 18.69M | 21.27M | 22.43M |
| Weighted Avg Shares (Diluted) | 16.54M | 17.14M | 18.69M | 21.27M | 22.43M |
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
Intrinsic Alpha fair value
Locked
Current Price
$398.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.